Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Caprion

This article was originally published in The Gray Sheet

Executive Summary

In vitro blood test for the human equivalent of mad cow disease, Creutzfeldt-Jacob disease (CJD), will be developed by the Ortho-Clinical Diagnostics unit of Johnson & Johnson under an exclusive, worldwide license agreement with Caprion Pharmaceuticals. The test will be based on prion technologies related to the monoclonal antibodies for CJD. Roche and Prionics also inked an agreement earlier this year for development of a CJD blood test (1"The Gray Sheet" Jan. 29, 2001, In Brief)...

You may also be interested in...



Abbott, ProMetic Pacts With Red Cross Cover Blood Screening, TSE Removal

The American Red Cross will retain a 74% equity stake in a joint venture with ProMetic Life Sciences to develop systems for detection and removal of transmissible spongiform encephalopathy (TSE) pathogens from blood and blood components

Roche Diagnostics/Prionics

Firms will collaborate in development of a blood test for the detection of Creutzfeldt-Jacob disease in humans under an agreement announced Jan. 24. CJD is related to bovine spongiform encephalopathy (BSE), or "mad cow disease." The deal also calls for Roche to distribute the Prionics-Check rapid test for the detection of BSE in dead cattle effective Feb. 1

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

UsernamePublicRestriction

Register

MT015815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel